Expert Perspectives on Advances in the Management of C. difficile - Episode 13

C. Difficile Treatment: Bezlotoxumab

The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.

EP. 1: C. Difficile Risk Factors and Manifestation
EP. 2: Strains of C. Difficile
EP. 3: Managing Community-Onset C. Difficile
EP. 4: Recurrent C. Difficile
EP. 5: C. Difficile: A Differential Diagnosis
EP. 6: Testing for C. Difficile Infections
EP. 7: Screening for C. Difficile
EP. 8: C. Difficile: Clinical Practice Guidelines and Treatment Options
EP. 9: C. Difficile: Updates to Clinical Practice Guidelines
EP. 10: Selecting Therapy to Treat C. Difficile
EP. 11: C. Difficile Treatment: Fidaxomicin
EP. 12: Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections
Now Viewing
EP. 13: C. Difficile Treatment: Bezlotoxumab
EP. 14: Preventing/Treating C. Difficile: Unmet Needs
EP. 15: Fecal Microbiota Transplantation for C. Difficile Infections
EP. 16: Emerging Treatment Options for C. Difficile Infections
EP. 17: C. Difficile: Barriers Treating With FMT
EP. 18: Making Strides in the Management of C. Difficile

Related Content:

Expert Perspectives on Advances in the Management of C. difficileC. DIFFICILEGASTROINTESTINAL INFECTIONS
RBX2660 for Recurrent CDI Associated with Microbiome and Bile Acid Restoration
New Therapeutic Repopulates the Gut Microbiome to Prevent Recurrent C Diff Infection
Hospitalized C Diff Patients May Pass Infection to Family